Forest, Eisai announce slim-downs

Share this article:

Forest Labs said today that its cost-savings initiative—dubbed Project Rejuvenate—is aimed at reducing operating expenses by $500 million. The company said it's focusing on three areas to save costs: realigning R&D, reducing marketing expenses, and slashing SG&A and other expenses. The Manhattan-based drugmaker said it expects to realize these plans by the end of FY2016.

Additionally, Forest announced it purchased US marketing rights for Merck's Saphris—a treatment for schizophrenia and acute bipolar mania. Merck will be paid $240 million in an upfront payment with the possibility of future payments for “defined sales milestones,” Forest said in a statement. Saphris recorded net sales of $120 million for the 12-month period ending September 30, 2013.

Eisai, meanwhile, announced late last week that it will cut 130 positions in the US and Europe. According to a statement by the Tokyo-based drug manufacturer, the cuts are a part of its goal of "focusing and strengthening product creation capabilities."
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.